Europe leads cannabis R&D
While Europe trails behind countries like the US in medicinal cannabis adoption, it’s uniquely positioned to revolutionise its research and development. The complexity of cannabis, with its myriad of cannabinoids, challenges the traditional drug development approach. However, Europe’s strong biomedical collaboration history and its utilisation of real-world data, like the UK’s Medical Cannabis Registry, can streamline this process. Despite global research lagging due to past restrictions, increased funding and inter-company collaborations hint at a bright future for Europe in advancing cannabis-based medicine and ensuring broader patient access.
Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.
